Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer.

Kregel S, Malik R, Asangani IA, Wilder-Romans K, Rajendiran T, Xiao L, Vo JN, Soni T, Cieslik M, Fernadez-Salas E, Zhou B, Cao X, Speers C, Wang S, Chinnaiyan AM.

Clin Cancer Res. 2019 Mar 27. doi: 10.1158/1078-0432.CCR-18-3776. [Epub ahead of print]

PMID:
30918020
2.

Thymidylate synthase maintains the de-differentiated state of triple negative breast cancers.

Siddiqui A, Gollavilli PN, Schwab A, Vazakidou ME, Ersan PG, Ramakrishnan M, Pluim D, Coggins S, Saatci O, Annaratone L, Hm Schellens J, Kim B, Asangani IA, Rasheed SAK, Marchiò C, Sahin O, Ceppi P.

Cell Death Differ. 2019 Feb 8. doi: 10.1038/s41418-019-0289-6. [Epub ahead of print]

3.

EWS/ETS-Driven Ewing Sarcoma Requires BET Bromodomain Proteins.

Gollavilli PN, Pawar A, Wilder-Romans K, Natesan R, Engelke CG, Dommeti VL, Krishnamurthy PM, Nallasivam A, Apel IJ, Xu T, Qin ZS, Feng FY, Asangani IA.

Cancer Res. 2018 Aug 15;78(16):4760-4773. doi: 10.1158/0008-5472.CAN-18-0484. Epub 2018 Jun 13.

PMID:
29898995
4.

Resistance to BET Inhibitor Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer.

Pawar A, Gollavilli PN, Wang S, Asangani IA.

Cell Rep. 2018 Feb 27;22(9):2236-2245. doi: 10.1016/j.celrep.2018.02.011.

5.

The depalmitoylase APT1 directs the asymmetric partitioning of Notch and Wnt signaling during cell division.

Stypulkowski E, Asangani IA, Witze ES.

Sci Signal. 2018 Jan 2;11(511). pii: eaam8705. doi: 10.1126/scisignal.aam8705.

6.

miR-34a Regulates Expression of the Stathmin-1 Oncoprotein and Prostate Cancer Progression.

Chakravarthi BVSK, Chandrashekar DS, Agarwal S, Balasubramanya SAH, Pathi SS, Goswami MT, Jing X, Wang R, Mehra R, Asangani IA, Chinnaiyan AM, Manne U, Sonpavde G, Netto GJ, Gordetsky J, Varambally S.

Mol Cancer Res. 2018 Jul;16(7):1125-1137. doi: 10.1158/1541-7786.MCR-17-0230. Epub 2017 Oct 12. Erratum in: Mol Cancer Res. 2018 Jul;16(7):1205-1206.

PMID:
29025958
7.

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM.

Cancer Cell. 2017 Jun 12;31(6):844-847. doi: 10.1016/j.ccell.2017.05.001. No abstract available.

8.

Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer.

Wang X, Qiao Y, Asangani IA, Ateeq B, Poliakov A, Cieślik M, Pitchiaya S, Chakravarthi BVSK, Cao X, Jing X, Wang CX, Apel IJ, Wang R, Tien JC, Juckette KM, Yan W, Jiang H, Wang S, Varambally S, Chinnaiyan AM.

Cancer Cell. 2017 Apr 10;31(4):532-548.e7. doi: 10.1016/j.ccell.2017.02.017. Epub 2017 Mar 23. Erratum in: Cancer Cell. 2017 Jun 12;31(6):844-847.

9.

BET Bromodomain Inhibitors Enhance Efficacy and Disrupt Resistance to AR Antagonists in the Treatment of Prostate Cancer.

Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2016 Apr;14(4):324-31. doi: 10.1158/1541-7786.MCR-15-0472. Epub 2016 Jan 20.

10.

Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth.

Mody RJ, Wu YM, Lonigro RJ, Cao X, Roychowdhury S, Vats P, Frank KM, Prensner JR, Asangani I, Palanisamy N, Dillman JR, Rabah RM, Kunju LP, Everett J, Raymond VM, Ning Y, Su F, Wang R, Stoffel EM, Innis JW, Roberts JS, Robertson PL, Yanik G, Chamdin A, Connelly JA, Choi S, Harris AC, Kitko C, Rao RJ, Levine JE, Castle VP, Hutchinson RJ, Talpaz M, Robinson DR, Chinnaiyan AM.

JAMA. 2015 Sep 1;314(9):913-25. doi: 10.1001/jama.2015.10080.

11.

Galanin modulates the neural niche to favour perineural invasion in head and neck cancer.

Scanlon CS, Banerjee R, Inglehart RC, Liu M, Russo N, Hariharan A, van Tubergen EA, Corson SL, Asangani IA, Mistretta CM, Chinnaiyan AM, D'Silva NJ.

Nat Commun. 2015 Apr 28;6:6885. doi: 10.1038/ncomms7885.

12.

Targeting the MLL complex in castration-resistant prostate cancer.

Malik R, Khan AP, Asangani IA, Cieślik M, Prensner JR, Wang X, Iyer MK, Jiang X, Borkin D, Escara-Wilke J, Stender R, Wu YM, Niknafs YS, Jing X, Qiao Y, Palanisamy N, Kunju LP, Krishnamurthy PM, Yocum AK, Mellacheruvu D, Nesvizhskii AI, Cao X, Dhanasekaran SM, Feng FY, Grembecka J, Cierpicki T, Chinnaiyan AM.

Nat Med. 2015 Apr;21(4):344-52. doi: 10.1038/nm.3830. Epub 2015 Mar 30.

13.

ERG/AKR1C3/AR Constitutes a Feed-Forward Loop for AR Signaling in Prostate Cancer Cells.

Powell K, Semaan L, Conley-LaComb MK, Asangani I, Wu YM, Ginsburg KB, Williams J, Squire JA, Maddipati KR, Cher ML, Chinni SR.

Clin Cancer Res. 2015 Jun 1;21(11):2569-79. doi: 10.1158/1078-0432.CCR-14-2352. Epub 2015 Mar 9.

14.

The lncRNA PCAT29 inhibits oncogenic phenotypes in prostate cancer.

Malik R, Patel L, Prensner JR, Shi Y, Iyer MK, Subramaniyan S, Carley A, Niknafs YS, Sahu A, Han S, Ma T, Liu M, Asangani IA, Jing X, Cao X, Dhanasekaran SM, Robinson DR, Feng FY, Chinnaiyan AM.

Mol Cancer Res. 2014 Aug;12(8):1081-7. doi: 10.1158/1541-7786.MCR-14-0257. Epub 2014 Jul 16.

15.

BETs abet Tam-R in ER-positive breast cancer.

Alluri PG, Asangani IA, Chinnaiyan AM.

Cell Res. 2014 Aug;24(8):899-900. doi: 10.1038/cr.2014.90. Epub 2014 Jul 8.

16.

BETting on a new prostate cancer treatment.

Asangani IA, Chinnaiyan AM.

Cell Cycle. 2014;13(13):2015-6. doi: 10.4161/cc.29459. Epub 2014 Jun 6. No abstract available.

17.

Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM.

Nature. 2014 Jun 12;510(7504):278-82. doi: 10.1038/nature13229. Epub 2014 Apr 23.

18.

The IncRNAs PCGEM1 and PRNCR1 are not implicated in castration resistant prostate cancer.

Prensner JR, Sahu A, Iyer MK, Malik R, Chandler B, Asangani IA, Poliakov A, Vergara IA, Alshalalfa M, Jenkins RB, Davicioni E, Feng FY, Chinnaiyan AM.

Oncotarget. 2014 Mar 30;5(6):1434-8.

19.

The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex.

Prensner JR, Iyer MK, Sahu A, Asangani IA, Cao Q, Patel L, Vergara IA, Davicioni E, Erho N, Ghadessi M, Jenkins RB, Triche TJ, Malik R, Bedenis R, McGregor N, Ma T, Chen W, Han S, Jing X, Cao X, Wang X, Chandler B, Yan W, Siddiqui J, Kunju LP, Dhanasekaran SM, Pienta KJ, Feng FY, Chinnaiyan AM.

Nat Genet. 2013 Nov;45(11):1392-8. doi: 10.1038/ng.2771. Epub 2013 Sep 29.

20.

The role of sarcosine metabolism in prostate cancer progression.

Khan AP, Rajendiran TM, Ateeq B, Asangani IA, Athanikar JN, Yocum AK, Mehra R, Siddiqui J, Palapattu G, Wei JT, Michailidis G, Sreekumar A, Chinnaiyan AM.

Neoplasia. 2013 May;15(5):491-501.

21.

Characterization of the EZH2-MMSET histone methyltransferase regulatory axis in cancer.

Asangani IA, Ateeq B, Cao Q, Dodson L, Pandhi M, Kunju LP, Mehra R, Lonigro RJ, Siddiqui J, Palanisamy N, Wu YM, Cao X, Kim JH, Zhao M, Qin ZS, Iyer MK, Maher CA, Kumar-Sinha C, Varambally S, Chinnaiyan AM.

Mol Cell. 2013 Jan 10;49(1):80-93. doi: 10.1016/j.molcel.2012.10.008. Epub 2012 Nov 15.

22.

Role of transcriptional corepressor CtBP1 in prostate cancer progression.

Wang R, Asangani IA, Chakravarthi BV, Ateeq B, Lonigro RJ, Cao Q, Mani RS, Camacho DF, McGregor N, Schumann TE, Jing X, Menawat R, Tomlins SA, Zheng H, Otte AP, Mehra R, Siddiqui J, Dhanasekaran SM, Nyati MK, Pienta KJ, Palanisamy N, Kunju LP, Rubin MA, Chinnaiyan AM, Varambally S.

Neoplasia. 2012 Oct;14(10):905-14.

23.

Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma.

Asangani IA, Harms PW, Dodson L, Pandhi M, Kunju LP, Maher CA, Fullen DR, Johnson TM, Giordano TJ, Palanisamy N, Chinnaiyan AM.

Oncotarget. 2012 Sep;3(9):1011-25.

24.

Expressed pseudogenes in the transcriptional landscape of human cancers.

Kalyana-Sundaram S, Kumar-Sinha C, Shankar S, Robinson DR, Wu YM, Cao X, Asangani IA, Kothari V, Prensner JR, Lonigro RJ, Iyer MK, Barrette T, Shanmugam A, Dhanasekaran SM, Palanisamy N, Chinnaiyan AM.

Cell. 2012 Jun 22;149(7):1622-34. doi: 10.1016/j.cell.2012.04.041.

25.

The mutational landscape of lethal castration-resistant prostate cancer.

Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA.

Nature. 2012 Jul 12;487(7406):239-43. doi: 10.1038/nature11125.

26.

Characterization of KRAS rearrangements in metastatic prostate cancer.

Wang XS, Shankar S, Dhanasekaran SM, Ateeq B, Sasaki AT, Jing X, Robinson D, Cao Q, Prensner JR, Yocum AK, Wang R, Fries DF, Han B, Asangani IA, Cao X, Li Y, Omenn GS, Pflueger D, Gopalan A, Reuter VE, Kahoud ER, Cantley LC, Rubin MA, Palanisamy N, Varambally S, Chinnaiyan AM.

Cancer Discov. 2011 Jun;1(1):35-43. doi: 10.1158/2159-8274.CD-10-0022. Epub 2011 Jun 1.

27.

Promoter cloning and characterization of the human programmed cell death protein 4 (pdcd4) gene: evidence for ZBP-89 and Sp-binding motifs as essential Pdcd4 regulators.

Leupold JH, Asangani IA, Mudduluru G, Allgayer H.

Biosci Rep. 2012 Jun;32(3):281-97. doi: 10.1042/BSR20110045.

PMID:
22111549
28.

Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer.

Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, Asangani IA, Iyer M, Maher CA, Grasso CS, Lonigro RJ, Quist M, Siddiqui J, Mehra R, Jing X, Giordano TJ, Sabel MS, Kleer CG, Palanisamy N, Natrajan R, Lambros MB, Reis-Filho JS, Kumar-Sinha C, Chinnaiyan AM.

Nat Med. 2011 Nov 20;17(12):1646-51. doi: 10.1038/nm.2580.

29.

Coordinated regulation of polycomb group complexes through microRNAs in cancer.

Cao Q, Mani RS, Ateeq B, Dhanasekaran SM, Asangani IA, Prensner JR, Kim JH, Brenner JC, Jing X, Cao X, Wang R, Li Y, Dahiya A, Wang L, Pandhi M, Lonigro RJ, Wu YM, Tomlins SA, Palanisamy N, Qin Z, Yu J, Maher CA, Varambally S, Chinnaiyan AM.

Cancer Cell. 2011 Aug 16;20(2):187-99. doi: 10.1016/j.ccr.2011.06.016.

30.

Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression.

Prensner JR, Iyer MK, Balbin OA, Dhanasekaran SM, Cao Q, Brenner JC, Laxman B, Asangani IA, Grasso CS, Kominsky HD, Cao X, Jing X, Wang X, Siddiqui J, Wei JT, Robinson D, Iyer HK, Palanisamy N, Maher CA, Chinnaiyan AM.

Nat Biotechnol. 2011 Jul 31;29(8):742-9. doi: 10.1038/nbt.1914.

31.

Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer.

Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM.

Cancer Cell. 2011 May 17;19(5):664-78. doi: 10.1016/j.ccr.2011.04.010. Erratum in: Cancer Cell. 2013 Apr 15;23(4):557.

32.

Therapeutic targeting of SPINK1-positive prostate cancer.

Ateeq B, Tomlins SA, Laxman B, Asangani IA, Cao Q, Cao X, Li Y, Wang X, Feng FY, Pienta KJ, Varambally S, Chinnaiyan AM.

Sci Transl Med. 2011 Mar 2;3(72):72ra17. doi: 10.1126/scitranslmed.3001498.

33.

Curcumin regulates miR-21 expression and inhibits invasion and metastasis in colorectal cancer.

Mudduluru G, George-William JN, Muppala S, Asangani IA, Kumarswamy R, Nelson LD, Allgayer H.

Biosci Rep. 2011 Jun;31(3):185-97. doi: 10.1042/BSR20100065.

PMID:
20815812
34.

First evidence that the antimalarial drug artesunate inhibits invasion and in vivo metastasis in lung cancer by targeting essential extracellular proteases.

Rasheed SA, Efferth T, Asangani IA, Allgayer H.

Int J Cancer. 2010 Sep 1;127(6):1475-85. doi: 10.1002/ijc.25315.

35.

Cetuximab attenuates metastasis and u-PAR expression in non-small cell lung cancer: u-PAR and E-cadherin are novel biomarkers of cetuximab sensitivity.

Nikolova DA, Asangani IA, Nelson LD, Hughes DP, Siwak DR, Mills GB, Harms A, Buchholz E, Pilz LR, Manegold C, Allgayer H.

Cancer Res. 2009 Mar 15;69(6):2461-70. doi: 10.1158/0008-5472.CAN-08-3236. Epub 2009 Mar 10.

36.
37.

NRF-1, and AP-1 regulate the promoter of the human calpain small subunit 1 (CAPNS1) gene.

Asangani IA, Rasheed SA, Leupold JH, Post S, Allgayer H.

Gene. 2008 Feb 29;410(1):197-206. doi: 10.1016/j.gene.2007.12.009. Epub 2007 Dec 23.

PMID:
18234454
38.
39.

MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer.

Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H.

Oncogene. 2008 Apr 3;27(15):2128-36. Epub 2007 Oct 29.

PMID:
17968323
40.

Src induces urokinase receptor gene expression and invasion/intravasation via activator protein-1/p-c-Jun in colorectal cancer.

Leupold JH, Asangani I, Maurer GD, Lengyel E, Post S, Allgayer H.

Mol Cancer Res. 2007 May;5(5):485-96.

41.

Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors.

Leupold JH, Yang HS, Colburn NH, Asangani I, Post S, Allgayer H.

Oncogene. 2007 Jul 5;26(31):4550-62. Epub 2007 Feb 12.

PMID:
17297470
42.

Identification of an histone H3 acetylated/K4-methylated-bound intragenic enhancer regulatory for urokinase receptor expression.

Wang H, Yan C, Asangani I, Allgayer H, Boyd DD.

Oncogene. 2007 Mar 29;26(14):2058-70. Epub 2006 Sep 25.

PMID:
17001307
43.

Supplemental Content

Loading ...
Support Center